Comparison of clinical efficacy and safety of weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel-group, multicentre, open-label trial (COMING study).
Tomohiko KimuraYukino KatakuraMasashi ShimodaFumiko KawasakiMizuho YamabeFuminori TatsumiMichihiro MatsukiYuichiro IwamotoTakatoshi AnnoYoshiro FushimiShinji KameiYukiko KimuraShuhei NakanishiTomoatsu MuneKohei KakuHideaki Kanetonull nullPublished in: Diabetes, obesity & metabolism (2023)
This prospective trial showed that semaglutide has more pronounced glucose- and body mass index-lowering effects and reduces liver fat percentage and visceral fat area and that dulaglutide has less gastrointestinal symptoms and superior Diabetes Treatment-Related Quality of Life scores related to pain and gastrointestinal symptoms.
Keyphrases
- phase iii
- open label
- phase ii
- study protocol
- clinical trial
- double blind
- body mass index
- adipose tissue
- placebo controlled
- type diabetes
- randomized controlled trial
- phase ii study
- chronic pain
- cardiovascular disease
- sleep quality
- insulin resistance
- physical activity
- squamous cell carcinoma
- glycemic control
- radiation therapy
- spinal cord injury
- cross sectional
- skeletal muscle
- spinal cord
- combination therapy